SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

CCP TECHNOLOGIES LIMITED (CT1)

Former Name ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 FROMTO
CONSTELLATION TECHNOLOGIES LIMITED04/06/2020
CCP TECHNOLOGIES LIMITED23/11/201604/06/2020
AGENIX LIMITED22/06/200123/11/2016
BIOTECH INTERNATIONAL LIMITED06/07/198922/06/2001
UNIFUND AUSTRALIA LIMITED06/07/1989

Shareholder links

Our website ranking of CT1: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Advanced Share Registry Services, 110 Stirling Hwy, Nedlands WA 6009

Tel : +61 8 9389 8033
Fax : +61 8 9262 3723
RegistryWebsite RegistryEmail

Company details

Address: Level 7, 420 Collins Street, Melbourne, VIC, 3000
Tel:  +61 3 8592 4883 Fax: +61 3 8616 0382

Date first listed: 08/10/1987
Company Secretary: Terri Bakos
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Cardiovascular diagnostic products

name changed to Constellation Technologies Limited

04/06/2020

The suspension of trading in the securities of CCP Technologies Limited will be lifted immediately following the release by CT1 of an announcement regarding its non-renounceable entitlement issue.

18/10/2019

The company announces a one for one non-renounceable pro rata entitlement issue. One free attaching option for each share applied for will be granted. The rights issue will be availalbe to holders of shaers in the company with a registered address in Australia and New Zealand as at 24 October 2019.

18/10/2019

The securities of CCP Technologies Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CT1, pending the release of an announcement regarding the final execution of agreements relating to the entitlement offer.

17/10/2019

The suspension of trading in the securities of CCP Technologies Limited will be lifted immediately following the release by CT1 of an announcement advising that it has withdrawn from discussions in relation to a potential acquisition.

24/07/2019

The company has withdrawn from the potential corporate transaction discussions. There were and are no binding commercial terms in place in respect to the potential transaction. The company will focus on other commercial and potential corporate opportunities.

24/07/2019

The company has received commitments from investors to raise $576,592 by issue of 44,353,252 new ordinary shares at $0.013 per share. The shares will be issued from the company's remaining placement capacity under Listing Rule 7.1. The company seeks an extension of the suspension of its securities in order to further progress the discussions in connection with the potential corporate transaction and to subsequently finalise an announcement in relation to those discussions. The company expects to make an announcement regarding this by the commencement of trade on 24 July 2019.

19/07/2019

The securities of CCP Technologies Limited will be suspended from quotation immediately under ListingbRule 17.2, at the request of CT1, pending the release of an announcement regarding proposed capital raising and the potential corporate transaction.

17/07/2019

The suspension of trading in the securities of CCP Technologies Limited will be lifted immediately, following release of an announcement of a proposed capital raising and the Company's response to an ASX Query.

17/07/2018

The company issues a response to an ASX query.

17/07/2018

The company has received commitments from strategic investors to raise $861,247 (before costs) by issue of 43,062,350 new ordinary shares at $0.02 per share. Each subscriber in the placement will also receive a two-year unlisted option, for each share issued, with an exercise price of $0.03, subject to shareholder approval at the Company's 2018 Annual General Meeting. CCP welcomes Penta Global Blockchain Foundation and First Growth Funds to the register. The company also announces the acceleration of CCP's blockchain initiatives.

17/07/2018

The securities of CCP Technologies Limited will be suspended from quotation immediately, in accordance with Listing Rule 17.3, pending the release of a satisfactory announcement in relation to the Company's proposed capital raising.

13/07/2018

name changed from Agenix Limited

23/11/2016

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

The global cardiovascular monitoring and diagnostic devices market to reach nearly US$ 8 Billion by 2021, growing at a CAGR of 9.0% from 2017 to 2021. Market by device or product type (ECG systems, resting ECG systems, stress ECG systems, cardiovascular diagnostic catheters, event monitors, Holter monitors, implantable loop recorders, ECG management systems). Major players are Boston Scientific Corporation, Covidien plc, FUKUDA DENSHI Co., Ltd., GE Healthcare, Johnson & Johnson, Medtronic, Inc, Nihon Kohden Corporation, Philips Healthcare, Siemens Healthcare, Sorin Group, Spacelabs Healthcare, St. Jude Medical, Inc and Welch Allyn, Inc.

https://www.ihealthcareanalyst.com/report/cardiovascular-monitoring-diagnostic-devices-market/

27/12/2017 00:17:24

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    18/10/2019Anoosh Manzoori1,000,000$0.012$12,000
    19/09/2017Adam Gallagher395,000$0.019$7,632
    07/09/2017Anthony Rowley85,000$0.024$2,037
    27/04/2017Michael White 50,000$0.022$1,122
    21/04/2017Anthony Rowley868,500$0.018$16,002

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Leath NicholsonNon Exec Chairman, Independent Director14/10/2016
    Terri BakosCFO01/01/2019
    Anoosh ManzooriIndependent Director14/10/2016
    Adam GallagherDirector, CEO01/06/2015

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Phillip HainsCFO09/11/201717/12/2019
    Anthony RowleyDirector, COO07/09/201608/02/2019
    Michael White Director, CEO07/09/201608/02/2019
    Garry TaylorCFO31/03/201109/11/2017
    Chris McNamaraNon Exec Director01/02/200806/03/2017
    Craig ChapmanNon Exec Director21/05/201318/11/2016
    Nicholas WestonExecutive Chairman, CEO22/08/200801/06/2015
    Anthony LeeNon Exec Director27/08/200712/11/2014
    Datuk LeeNon Exec Director27/08/200712/11/2014
    Stephen PhuaCEO04/01/2010
    Jonathan ZhangNon Exec Director30/10/2009
    Gordon Crosbie-WalshNon Exec Director01/02/200812/08/2008
    James LiuNon Exec Director12/08/2008
    Ravindran GovindanNon Exec Chairman13/06/200008/08/2008
    Neil LeggettCompany Secretary01/05/200329/05/2008
    Andre LamotteNon Exec Director28/09/200509/05/2008
    Karl SchlobohmCompany Secretary16/12/200531/01/2008
    Gim-Choon AngNon Exec Director31/08/2007
    Fong WongNon Exec Director11/08/200012/12/2006
    Myles DaveyNon Exec Director20/11/2006
    Donald HomeCEO15/12/2005
    Katherine WoodthorpeNon Exec Director21/06/200108/05/2003
    Mark CarnegieNon Exec Director17/11/200010/12/2002

    Date of first appointment, title may have changed.